11-112089001-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_003002.4(SDHD):c.304C>T(p.His102Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H102L) has been classified as Pathogenic.
Frequency
Consequence
NM_003002.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SDHD | NM_003002.4 | c.304C>T | p.His102Tyr | missense_variant | 3/4 | ENST00000375549.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SDHD | ENST00000375549.8 | c.304C>T | p.His102Tyr | missense_variant | 3/4 | 1 | NM_003002.4 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Pheochromocytoma;C1847319:Carney-Stratakis syndrome;C1868633:Paragangliomas with sensorineural hearing loss;CN166604:Cowden syndrome 3 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Invitae | Nov 25, 2019 | This sequence change replaces histidine with tyrosine at codon 102 of the SDHD protein (p.His102Tyr). The histidine residue is highly conserved and there is a moderate physicochemical difference between histidine and tyrosine. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.His102 amino acid residue in SDHD. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10657297, 12811540, 19454582, 22025150, 22241717). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed in individual(s) with paraganglioma-pheochromocytoma syndrome (PMID: 22241717, Invitae). This variant is not present in population databases (ExAC no frequency). - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 17, 2020 | The p.H102Y pathogenic mutation (also known as c.304C>T), located in coding exon 3 of the SDHD gene, results from a C to T substitution at nucleotide position 304. The histidine at codon 102 is replaced by tyrosine, an amino acid with few similar properties. This variant has been reported in multiple individuals with a clinical diagnossis of paraganglioma-pheochromocytoma (PGL/PCC) syndrome (Piccini V et al. Endocr. Relat. Cancer. 2012 Apr;19(2):149-55; Bacca A et al. Head Neck. 2013 Jan;35(1):23-7; Benn DE et al. Endocr. Relat. Cancer. 2015 Aug;22:T91-103). Several other variants at the same codon (p.H102L, p.H102R, p.H102Y, and p.H102P) have been described in individuals with head and neck paraganglioma (Poeppel TD et al J. Clin. Oncol. 2011 Nov;29(33):e812-5; Piccini V et al. Endocr. Relat. Cancer. 2012 Apr;19(2):149-55; Baysal BE et al. Science. 2000 Feb;287(5454):848-51; Burnichon N et al. J. Clin. Endocrinol. Metab. 2009 Aug;94(8):2817-27). Based on internal structural analysis, this variant is anticipated to disrupt a region of known function (Ambry internal data; Sun F et al. Cell. 2005 Jul;121(7):1043-57; Zhou Q et al. Protein Cell. 2011 Jul;2(7):531-42). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at